• Camille Ehre, Zachary L Rushton, Boya Wang, Lauren N Hothem, Cameron B Morrison, Nicholas C Fontana, Matthew R Markovetz, Martial F Delion, Takafumi Kato, Diane Villalon, William R Thelin, Charles R Esther, David B Hill, Barbara R Grubb, Alessandra Livraghi-Butrico, Scott H Donaldson, and Richard C Boucher.
• 1 Marsico Lung Institute and.
• Am. J. Respir. Crit. Care Med. 2019 Jan 15; 199 (2): 171180171-180.

RationaleAirways obstruction with thick, adherent mucus is a pathophysiologic and clinical feature of muco-obstructive respiratory diseases, including chronic obstructive pulmonary disease, asthma, and cystic fibrosis (CF). Mucins, the dominant biopolymer in mucus, organize into complex polymeric networks via the formation of covalent disulfide bonds, which govern the viscoelastic properties of the mucus gel. For decades, inhaled N-acetylcysteine (NAC) has been used as a mucolytic to reduce mucin disulfide bonds with little, if any, therapeutic effects. Improvement of mucolytic therapy requires the identification of NAC deficiencies and the development of compounds that overcome them.ObjectivesElucidate the pharmacological limitations of NAC and test a novel mucin-reducing agent, P3001, in preclinical settings.MethodsThe study used biochemical (e.g., Western blotting, mass spectrometry) and biophysical assays (e.g., microrheology/macrorheology, spinnability, mucus velocity measurements) to test compound efficacy and toxicity in in vitro and in vivo models and patient sputa.Measurements And Main ResultsDithiothreitol and P3001 were directly compared with NAC in vitro and both exhibited superior reducing activities. In vivo, P3001 significantly decreased lung mucus burden in βENaC-overexpressing mice, whereas NAC did not (n = 6-24 mice per group). In NAC-treated CF subjects (n = 5), aerosolized NAC was rapidly cleared from the lungs and did not alter sputum biophysical properties. In contrast, P3001 acted faster and at lower concentrations than did NAC, and it was more effective than DNase in CF sputum ex vivo.ConclusionsThese results suggest that reducing the viscoelasticity of airway mucus is an achievable therapeutic goal with P3001 class mucolytic agents.

30 keywords...

hide…